Document Detail


Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
MedLine Citation:
PMID:  21407187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD.
Authors:
Khurram J Khan; Thomas A Ullman; Alexander C Ford; Maria T Abreu; Amir Abadir; A Abadir; John K Marshall; Nicholas J Talley; Paul Moayyedi
Related Documents :
11598477 - Anocutaneous advancement flap repair of transsphincteric fistulas.
6663417 - The lateral reservoir technique of ileal endorectal pull-through for ulcerative colitis...
15868497 - Anterolateral rectopexy for correction of rectoceles leads to good anatomical but poor ...
12972967 - Excision of thrombosed external hemorrhoid under local anesthesia: a retrospective eval...
23623817 - Correlation between inflammation state and successful medical cardioversion using bepri...
18515507 - Antibiotic prophylaxis for prevention of postpartum perineal wound complications: a ran...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review     Date:  2011-03-15
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  106     ISSN:  1572-0241     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-06     Completed Date:  2011-06-06     Revised Date:  2011-06-20    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  661-73     Citation Subset:  IM    
Affiliation:
McMaster University Medical Centre, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use*
Colitis, Ulcerative / drug therapy*,  physiopathology
Crohn Disease / drug therapy*,  physiopathology
Drug Combinations
Humans
Randomized Controlled Trials as Topic
Recurrence / prevention & control
Remission Induction / methods
Rifamycins / therapeutic use
Risk
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Drug Combinations; 0/Rifamycins
Comments/Corrections
Erratum In:
Am J Gastroenterol. 2011 May;106(5):1014
Note: Abadir, A [corrected to Abadir, Amir]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-A...
Next Document:  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis.